From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

What to think after temporary power company Aggreko gets bid for?

By Chris Bailey of Financial Orbit | Monday 8 February 2021


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Back in November 2018 here, I concluded about temporary power company Aggreko (AGK) that it was worth 30% more than its c.750p share price then.  However, returns in 2019 were reversed in 2020 as the Olympics did not happen and emerging market demand was hit by a bunch of “challenges” as well.  Still – by last month – Aggreko gave a short update which concluded that its cautious £80-100 million profit target for 2020 was likely to be slightly beaten.  And to highlight improving prospects, it saw 2021’s profits to be back to the £170-190 million range.  That is not too shabby for a company trading back in late January at an EV of about £1.7 billion.  

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

ARB

Worthless Argo what news Helios?

Sunday »

Bearcast

Tom Winnifrith Bearcast: macrobabble calls

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

 

PICH

Pitch Pit – this stinks

Time left: 22:39:12